Angiotensin type 2 receptor (AT2R) and receptor Mas: A complex liaison

Clinical Science

Volumn 128, Issue 4, 2015, Pages 227-234

  Villela, Daniel ^a,b   Leonhardt, Julia ^b   Patel, Neal ^c   Joseph, Jason ^c   Kirsch, Sebastian ^b   Hallberg, Anders ^d   Unger, Thomas ^e   Bader, Michael ^f   Santos, Robson A ^a   Sumners, Colin ^c   Steckelings, U Muscha ^b,g  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF FLORIDA   (United States)

^d UPPSALA UNIVERSITY   (Sweden)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^g UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Angiotensin type 2 receptor (AT2R); Mas receptor; Renin angiotensin system (RAS)

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN[1-7]; G PROTEIN COUPLED RECEPTOR; MAS RECEPTOR; MAS RELATED G PROTEIN COUPLED RECEPTOR; UNCLASSIFIED DRUG; LIGAND; ONCOPROTEIN; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MAS-1;

ARTICLE; DIMERIZATION; DRUG PROTEIN BINDING; HUMAN; LIGAND BINDING; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; ANIMAL; METABOLISM;

ANIMALS; HUMANS; LIGANDS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84924281052     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20130515     Document Type: Article

References (76)

1. Steckelings, U. M. and Unger, T. (2008) The renin-angiotensin- aldosterone system. Manual of Hypertension of the European Society of Hypertension, 1st edn (Mancia, G., Grassi, G. and Kjeldsen, S. E., eds), pp. 110-116, Informa Healthcare, London
2. Paulis, L., Steckelings, U. M. and Unger, T. (2012) Key advances in antihypertensive treatment. Nat. Rev. Cardiol. 9, 276-285
3. Krum, H. and Gilbert, R. E. (2007) Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders. J. Hypertens. 25, 25-35
4. De Gasparo, M., Catt, K. J., Inagami, T., Wright, J. W. and Unger, T. (2000) International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 52, 415-472
5. Lautner, R. Q., Villela, D. C., Fraga-Silva, R. A., Silva, N., Verano-Braga, T., Costa-Fraga, F., Jankowski, J., Jankowski, V., Sousa, F., Alzamora, A. et al. (2013) Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ. Res. 112, 1104-1111
6. Santos, R. A. S., Ferreira, A. J., Verano-Braga, T. and Bader, M. (2013) Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J. Endocrinol. 216, R1-R17
7. Iwai, M. and Horiuchi, M. (2009) Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hypertens. Res. 32, 533-536
8. Jones, E. S., Vinh, A., McCarthy, C. A., Gaspari, T. A. and Widdop, R. E. (2008) AT2 receptors: functional relevance in cardiovascular disease. Pharmacol. Ther. 120, 292-316
9. Steckelings, U. M., Kaschina, E. and Unger, T. (2005) The AT2 receptor-a matter of love and hate. Peptides 26, 1401-1409
10. Sumners, C., Horiuchi, M., Widdop, R. E., McCarthy, C., Unger, T. and Steckelings, U. M. (2013) Protective arms of the renin-angiotensin-system in neurological disease. Clin. Exp. Pharmacol. Physiol. 40, 580-588
11. Hein, L., Barsh, G. S., Pratt, R. E., Dzau, V. J. and Kobilka, B. K. (1995) Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 377, 744-747
12. Ichiki, T., Labosky, P. A., Shiota, C., Okuyama, S., Imagawa, Y., Fogo, A., Niimura, F., Ichikawa, I., Hogan, B. L. and Inagami, T. (1995) Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 377, 748-750
13. Adachi, Y., Saito, Y., Kishimoto, I., Harada, M., Kuwahara, K., Takahashi, N., Kawakami, R., Nakanishi, M., Nakagawa, Y., Tanimoto, K. et al. (2003) Angiotensin II type 2 receptor deficiency exacerbates heart failure and reduces survival after acute myocardial infarction in mice. Circulation 107, 2406-2408
14. Iwai, M., Liu, H.-W., Chen, R., Ide, A., Okamoto, S., Hata, R., Sakanaka, M., Shiuchi, T. and Horiuchi, M. (2004) Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 110, 843-848
15. Benndorf, R. A., Krebs, C., Hirsch-Hoffmann, B., Schwedhelm, E., Cieslar, G., Schmidt-Haupt, R., Steinmetz, O. M., Meyer-Schwesinger, C., Thaiss, F., Haddad, M. et al. (2009) Angiotensin II type 2 receptor deficiency aggravates renal injury and reduces survival in chronic kidney disease in mice. Kidney Int. 75, 1039-1049
16. Iwai, M., Chen, R., Li, Z., Shiuchi, T., Suzuki, J., Ide, A., Tsuda, M., Okumura, M., Min, L.-J., Mogi, M. et al. (2005) Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice. Circulation 112, 1636-1643
17. Tiyerili, V., Mueller, C. F. H., Becher, U. M., Czech, T., van Eickels, M., Daiber, A., Nickenig, G. and Wassmann, S. (2012) Stimulation of the AT2 receptor reduced atherogenesis in ApoE(-/-)/AT1A(-/-) double knock out mice. J. Mol. Cell. Cardiol. 52, 630-637
18. Santos, R. A. S., Simoes e Silva, A. C., Maric, C., Silva, D. M. R., Machado, R. P., de Buhr, I., Heringer-Walther, S., Pinheiro, S. V. B., Lopes, M. T., Bader, M. et al. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U.S.A. 100, 8258-8263
19. Bosnyak, S., Jones, E. S., Christopoulos, A., Aguilar, M.-I., Thomas, W. G. and Widdop, R. E. (2011) Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin. Sci. 121, 297-303
20. Carey, R. M. and Padia, S. H. (2013) Role of angiotensin AT2 receptors in natriuresis: intrarenal mechanisms and therapeutic potential. Clin. Exp. Pharmacol. Physiol. 40, 527-534
21. Kemp, B. A., Bell, J. F., Rottkamp, D. M., Howell, N. L., Shao, W., Navar, L. G., Padia, S. H. and Carey, R. M. (2012) Intrarenal angiotensin III is the predominant agonist for proximal tubule angiotensin type 2 receptors. Hypertension 60, 387-395
22. Hansen, J. L., Servant, G., Baranski, T. J., Fujita, T., Iiri, T. and Sheikh, S. P. (2000) Functional reconstitution of the angiotensin II type 2 receptor and G(i) activation. Circ. Res. 87, 753-759
23. Bedecs, K., Elbaz, N., Sutren, M., Masson, M., Susini, C., Strosberg, A. D. and Nahmias, C. (1997) Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase. Biochem. J. 325, 449-454
24. Gava, E., Samad-Zadeh, A., Zimpelmann, J., Bahramifarid, N., Kitten, G. T., Santos, R. A., Touyz, R. M. and Burns, K. D. (2009) Angiotensin-(1-7) activates a tyrosine phosphatase and inhibits glucose-induced signalling in proximal tubular cells. Nephrol. Dial. Transplant. 24, 1766-1773
25. Nouet, S. and Nahmias, C. (2000) Signal transduction from the angiotensin II AT2 receptor. Trends Endocrinol. Metab. 11, 1-6
26. Sampaio, W. O., Henrique de Castro, C., Santos, R. A. S., Schiffrin, E. L. and Touyz, R. M. (2007) Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension 50, 1093-1098
27. Rompe, F., Artuc, M., Hallberg, A., Alterman, M., Ströder, K., Thöne-Reineke, C., Reichenbach, A., Schacherl, J., Dahlöf, B., Bader, M. et al. (2010) Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension 55, 924-931
28. κB-dependent pathways. Br. J. Pharmacol. 166, 1964-1976
29. Gohlke, P., Pees, C. and Unger, T. (1998) AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 31, 349-355
30. Heitsch, H., Brovkovych, S., Malinski, T. and Wiemer, G. (2001) Angiotensin-(1-7)-Stimulated nitric oxide and superoxide release from endothelial cells. Hypertension 37, 72-76
31. Stegbauer, J., Potthoff, S. A., Quack, I., Mergia, E., Clasen, T., Friedrich, S., Vonend, O., Woznowski, M., Königshausen, E., Sellin, L. et al. (2011) Chronic treatment with angiotensin-(1-7) improves renal endothelial dysfunction in apolipoproteinEdeficient mice. Br. J. Pharmacol. 163, 974-983
32. AbdAlla, S., Lother, H., Abdel-tawab, A. M. and Quitterer, U. (2001) The angiotensin II AT2 receptor is an AT1 receptor antagonist. J. Biol. Chem. 276, 39721-39726
33. Kostenis, E., Milligan, G., Christopoulos, A., Sanchez-Ferrer, C. F., Heringer-Walther, S., Sexton, P. M., Gembardt, F., Kellett, E., Martini, L., Vanderheyden, P. et al. (2005) G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 111, 1806-1813
34. Roks, A. J. M., Nijholt, J., van Buiten, A., van Gilst, W. H., de Zeeuw, D. and Henning, R. H. (2004) Low sodium diet inhibits the local counter-regulator effect of angiotensin-(1-7) on angiotensin II. J. Hypertens. 22, 2355-2361
35. Gorelik, G., Carbini, L. A. and Scicli, A. G. (1998) Angiotensin 1-7 induces bradykinin-mediated relaxation in porcine coronary artery. J. Pharmacol. Exp. Ther. 286, 403-410
36. Bosnyak, S., Widdop, R. E., Denton, K. M. and Jones, E. S. (2012) Differential mechanisms of ang(1-7)-mediated vasodepressor effect in adult and aged candesartan-treated rats. Int. J. Hypertens. 2012, 192567
37. Walters, P. E., Gaspari, T. A. and Widdop, R. E. (2005) Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension 45, 960-966
38. Jaiswal, N., Diz, D. I., Chappell, M. C., Khosla, M. C. and Ferrario, C. M. (1992) Stimulation of endothelial cell prostaglandin production by angiotensin peptides. Characterization of receptors. Hypertension 19 (2 Suppl.), II49-II55
39. Tesanovic, S., Vinh, A., Gaspari, T. A., Casley, D. and Widdop, R. E. (2010) Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 30, 1606-1613
40. Costa, M. A., Lopez Verrilli, M. A., Gomez, K. A., Nakagawa, P., Peña, C., Arranz, C. and Gironacci, M. M. (2010) Angiotensin-(1-7) upregulates cardiac nitric oxide synthase in spontaneously hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 299, H1205-H1211
41. Muthalif, M. M., Benter, I. F., Uddin, M. R., Harper, J. L. and Malik, K. U. (1998) Signal transduction mechanisms involved in angiotensin-(1-7)-stimulated arachidonic acid release and prostanoid synthesis in rabbit aortic smooth muscle cells. J. Pharmacol. Exp. Ther. 284, 388-398
42. Durand, M. J., Raffai, G., Weinberg, B. D. and Lombard, J. H. (2010) Angiotensin-(1-7) and low-dose angiotensin II infusion reverse salt-induced endothelial dysfunction via different mechanisms in rat middle cerebral arteries. Am. J. Physiol. Heart Circ. Physiol. 299, H1024-H1033
43. De Souza, A. M., Lopes, A. G., Pizzino, C. P., Fossari, R. N., Miguel, N. C. O., Cardozo, F. P., Abi-Abib, R., Fernandes, M. S., Santos, D. P. A. and Caruso-Neves, C. (2004) Angiotensin II and angiotensin-(1-7) inhibit the inner cortex Na+-ATPase activity through AT2 receptor. Regul. Pept. 120, 167-175
44. Lara, L. da S., Cavalcante, F., Axelband, F., De Souza, A. M., Lopes, A. G. and Caruso-Neves, C. (2006) Involvement of the Gi/o/cGMP/PKG pathway in the AT2-mediated inhibition of outer cortex proximal tubule Na+-ATPase by Ang-(1-7). Biochem. J. 395, 183-190
45. Jiang, T., Gao, L., Zhu, X.-C., Yu, J.-T., Shi, J.-Q., Tan, M.-S., Lu, J., Tan, L. and Zhang, Y.-D. (2013) Angiotensin-(1-7) inhibits autophagy in the brain of spontaneously hypertensive rats. Pharmacol. Res. 71, 61-68
46. Mecca, A. P., Regenhardt, R. W., O'Connor, T. E., Joseph, J. P., Raizada, M. K., Katovich, M. J. and Sumners, C. (2011) Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke. Exp. Physiol. 96, 1084-1096
47. Wiemer, G., Dobrucki, L. W., Louka, F. R., Malinski, T. and Heitsch, H. (2002) AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension 40, 847-852
48. Pinheiro, S. V. B., Simões e Silva, A. C., Sampaio, W. O., de Paula, R. D., Mendes, E. P., Bontempo, E. D., Pesquero, J. B., Walther, T., Alenina, N., Bader, M. et al. (2004) Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension 44, 490-496
49. Wan, Y., Wallinder, C., Plouffe, B., Beaudry, H., Mahalingam, A. K., Wu, X., Johansson, B., Holm, M., Botoros, M., Karlén, A. et al. (2004) Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J. Med. Chem. 47, 5995-6008
50. Murugaiah, A. M. S., Wallinder, C., Mahalingam, A. K., Wu, X., Wan, Y., Plouffe, B., Botros, M., Karlén, A., Hallberg, M., Gallo-Payet, N. et al. (2007) Selective angiotensin II AT(2) receptor agonists devoid of the imidazole ring system. Bioorg. Med. Chem. 15, 7166-7183
51. Wu, X., Wan, Y., Mahalingam, A. K., Murugaiah, A. M. S., Plouffe, B., Botros, M., Karlén, A., Hallberg, M., Gallo-Payet, N. and Alterman, M. (2006) Selective angiotensin II AT2 receptor agonists: arylbenzylimidazole structure-activity relationships. J. Med. Chem. 49, 7160-7168
52. Barki-Harrington, L., Luttrell, L. M. and Rockman, H. A. (2003) Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. Circulation 108, 1611-1618
53. de Castro, C. H., dos Santos, R. A. S., Ferreira, A. J., Bader, M., Alenina, N. and de Almeida, A. P. (2005) Evidence for a functional interaction of the angiotensin-(1-7) receptor Mas with AT1 and AT2 receptors in the mouse heart. Hypertension 46, 937-942
54. Lyngsø, C., Erikstrup, N. and Hansen, J. L. (2009) Functional interactions between 7TM receptors in the renin-angiotensin system-dimerization or crosstalk? Mol. Cell. Endocrinol. 302, 203-212
55. Hansen, J. L., Theilade, J., Haunsø, S. and Sheikh, S. P. (2004) Oligomerization of wild type and nonfunctional mutant angiotensin II type I receptors inhibits galphaq protein signaling but not ERK activation. J. Biol. Chem. 279, 24108-24115
56. Karip, E., Turu, G., Süpeki, K., Szidonya, L. and Hunyady, L. (2007) Cross-inhibition of angiotensin AT1 receptors supports the concept of receptor oligomerization. Neurochem. Int. 51, 261-267
57. AbdAlla, S., Lother, H., Langer, A., el Faramawy, Y. and Quitterer, U. (2004) Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of atherosclerosis. Cell 119, 343-354
58. Miura, S.-I., Karnik, S. S. and Saku, K. (2005) Constitutively active homo-oligomeric angiotensin II type 2 receptor induces cell signaling independent of receptor conformation and ligand stimulation. J. Biol. Chem. 280, 18237-18244
59. Santos, E. L., Reis, R. I., Silva, R. G., Shimuta, S. I., Pecher, C., Bascands, J.-L., Schanstra, J. P., Oliveira, L., Bader, M., Paiva, A. C. M. et al. (2007) Functional rescue of a defective angiotensin II AT1 receptor mutant by the Mas protooncogene. Regul. Pept. 141, 159-167
60. Abadir, P. M., Periasamy, A., Carey, R. M. and Siragy, H. M. (2006) Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization. Hypertension 48, 316-322
61. Zeng, C., Luo, Y., Asico, L. D., Hopfer, U., Eisner, G. M., Felder, R. A. and Jose, P. A. (2003) Perturbation of D1 dopamine and AT1 receptor interaction in spontaneously hypertensive rats. Hypertension 42, 787-792
62. Zeng, C., Asico, L. D., Wang, X., Hopfer, U., Eisner, G. M., Felder, R. A. and Jose, P. A. (2003) Angiotensin II regulation of AT1 and D3 dopamine receptors in renal proximal tubule cells of SHR. Hypertension 41, 724-729
63. Zeng, C., Hopfer, U., Asico, L. D., Eisner, G. M., Felder, R. A. and Jose, P. A. (2005) Altered AT1 receptor regulation of ETB receptors in renal proximal tubule cells of spontaneously hypertensive rats. Hypertension 46, 926-931
64. Koid, S. S. and Campbell, D. J. (2013) Evolving concepts of the renin-angiotensin system: highlights from the pre-ISH 2012 satellite meeting. J. Renin Angiotensin Aldosterone Syst. 14, 93-96
65. Villela, D. C., Münter, L.-M., Multhaup, G., Mayer, M., Benz, V., Namsolleck, P., Unger, T., Bader, M., Santos, R. A. S. and Steckelings, U. M. (2012) Evidence of a direct MAS-AT2R dimerisation. J. Hypertens. 30, e117
66. Brosnihan, K. B., Li, P. and Ferrario, C. M. (1996) Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 27, 523-528
67. Dharmani, M., Mustafa, M. R., Achike, F. I. and Sim, M.-K. (2007) Effects of angiotensin 1-7 on the actions of angiotensin II in the renal and mesenteric vasculature of hypertensive and streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 561, 144-150
68. Jiang, T., Gao, L., Guo, J., Lu, J., Wang, Y. and Zhang, Y. (2012) Suppressing inflammation by inhibiting the NF-κB pathway contributes to the neuroprotective effect of angiotensin-(1-7) in rats with permanent cerebral ischaemia. Br. J. Pharmacol. 167, 1520-1532
69. Tallant, E. A., Ferrario, C. M. and Gallagher, P. E. (2005) Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am. J. Physiol. Heart Circ. Physiol. 289, H1560-H1566
70. Silva, D. M. R., Vianna, H. R., Cortes, S. F., Campagnole-Santos, M. J., Santos, R. A. S. and Lemos, V. S. (2007) Evidence for a new angiotensin-(1-7) receptor subtype in the aorta of Sprague-Dawley rats. Peptides 28, 702-707
71. Lemos, V. S., Silva, D. M. R., Walther, T., Alenina, N., Bader, M. and Santos, R. A. S. (2005) The endothelium-dependent vasodilator effect of the nonpeptide Ang(1-7) mimic AVE 0991 is abolished in the aorta of mas-knockout mice. J. Cardiovasc. Pharmacol. 46, 274-279
72. Gembardt, F., Van Veghel, R., Coffman, T. M., Schultheiss, H.-P., Danser, A. H. J. and Walther, T. (2012) Hemodynamic effects of vasorelaxant compounds in mice lacking one, two or all three angiotensin II receptors. Hypertens. Res. 35, 547-551
73. Ohshima, K., Mogi, M., Nakaoka, H., Iwanami, J., Min, L.-J., Kanno, H., Tsukuda, K., Chisaka, T., Bai, H.-Y., Wang, X.-L. et al. (2014) Possible role of angiotensin-converting enzyme 2 and activation of angiotensin II type 2 receptor by angiotensin-(1-7) in improvement of vascular remodeling by angiotensin II type 1 receptor blockade. Hypertension 63, e53-e59
74. Waldhoer, M., Fong, J., Jones, R. M., Lunzer, M. M., Sharma, S. K., Kostenis, E., Portoghese, P. S. and Whistler, J. L. (2005) A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc. Natl. Acad. Sci. U.S.A. 102, 9050-9055
75. Ferreira, A. J., Bader, M. and Santos, R. A. S. (2012) Therapeutic targeting of the angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas cascade in the renin-angiotensin system: a patent review. Expert Opin. Ther. Pat. 22, 567-574
76. Steckelings, U. M., Paulis, L., Namsolleck, P. and Unger, T. (2012) AT2 receptor agonists: hypertension and beyond. Curr. Opin. Nephrol. Hypertens. 21, 142-146